JP2018507166A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507166A5
JP2018507166A5 JP2017528877A JP2017528877A JP2018507166A5 JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5 JP 2017528877 A JP2017528877 A JP 2017528877A JP 2017528877 A JP2017528877 A JP 2017528877A JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5
Authority
JP
Japan
Prior art keywords
antibody
antibiotic
conjugate compound
alkyl
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528877A
Other languages
English (en)
Japanese (ja)
Other versions
JP6751393B2 (ja
JP2018507166A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063515 external-priority patent/WO2016090040A1/en
Publication of JP2018507166A publication Critical patent/JP2018507166A/ja
Publication of JP2018507166A5 publication Critical patent/JP2018507166A5/ja
Application granted granted Critical
Publication of JP6751393B2 publication Critical patent/JP6751393B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528877A 2014-12-03 2015-12-02 抗staphylococcus aureus抗体リファマイシン抱合体及びその使用 Expired - Fee Related JP6751393B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087213P 2014-12-03 2014-12-03
US62/087,213 2014-12-03
PCT/US2015/063515 WO2016090040A1 (en) 2014-12-03 2015-12-02 Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2018507166A JP2018507166A (ja) 2018-03-15
JP2018507166A5 true JP2018507166A5 (cg-RX-API-DMAC7.html) 2019-01-17
JP6751393B2 JP6751393B2 (ja) 2020-09-02

Family

ID=55022690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528877A Expired - Fee Related JP6751393B2 (ja) 2014-12-03 2015-12-02 抗staphylococcus aureus抗体リファマイシン抱合体及びその使用

Country Status (11)

Country Link
US (1) US20180125995A1 (cg-RX-API-DMAC7.html)
EP (1) EP3226908A1 (cg-RX-API-DMAC7.html)
JP (1) JP6751393B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170086542A (cg-RX-API-DMAC7.html)
CN (1) CN107249642A (cg-RX-API-DMAC7.html)
BR (1) BR112017011478A2 (cg-RX-API-DMAC7.html)
CA (1) CA2966211A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244230A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017007231A (cg-RX-API-DMAC7.html)
RU (1) RU2017118792A (cg-RX-API-DMAC7.html)
WO (1) WO2016090040A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
HK1222577A1 (zh) 2013-12-16 2017-07-07 Genentech Inc. 擬肽化合物及其抗體藥物偶聯物
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017152083A1 (en) * 2016-03-04 2017-09-08 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス,インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
CN111939256B (zh) * 2020-07-06 2022-05-31 中国药科大学 一种具有细菌调理特性的抗菌辅助材料及其制备方法和应用
US20250082761A1 (en) * 2021-08-20 2025-03-13 Rutgers, The State University Of New Jersey Dual-targeted rna polymerase inhibitors: conjugates of benzoxazino- and spiro-rifamycins with n alpha-aroyl-n-aryl-phenylalaninamides
US20250319024A1 (en) * 2021-08-27 2025-10-16 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4610919A (en) 1985-06-14 1986-09-09 Fiber Bond Corporation Binder for fibrous padding
JP2544375B2 (ja) 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
JP3963976B2 (ja) 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
CA2373221A1 (en) 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7017718B2 (en) * 2001-06-28 2006-03-28 Freni Brembo S.P.A Composite disc for a disc brake having a splittable braking band
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1482972A4 (en) 2001-11-20 2005-11-23 Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
EP1453837A4 (en) * 2001-11-21 2007-11-07 Activbiotics Inc TARGETED THERAPEUTIC AGENTS AND USES THEREOF
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
KR20070029616A (ko) 2003-08-22 2007-03-14 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005062882A2 (en) 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US8343928B2 (en) 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
KR101327635B1 (ko) * 2005-08-11 2013-11-12 타간타 테라퓨틱스 인크. 포스폰산화 리파마이신, 및 그의 뼈 및 관절 감염의 저지및 치료 용도
AU2006326456A1 (en) 2005-12-14 2007-06-21 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
CA2760493A1 (en) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US8524691B2 (en) 2008-08-13 2013-09-03 The Medicines Company Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
ES2718614T3 (es) * 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
SG177653A1 (en) 2009-07-15 2012-02-28 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
WO2012113847A1 (en) 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
AU2012395148B2 (en) * 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
BR112015029754A2 (pt) * 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
EP3381939A1 (en) 2013-05-31 2018-10-03 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
EP3082875B1 (en) * 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
HK1222577A1 (zh) * 2013-12-16 2017-07-07 Genentech Inc. 擬肽化合物及其抗體藥物偶聯物

Similar Documents

Publication Publication Date Title
JP2018507166A5 (cg-RX-API-DMAC7.html)
JP2018503603A5 (cg-RX-API-DMAC7.html)
RU2017118793A (ru) Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
RU2017118792A (ru) Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
TWI864472B (zh) 抗體的特異性偶聯
JP2016525343A5 (cg-RX-API-DMAC7.html)
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP2016502504A5 (cg-RX-API-DMAC7.html)
JP2018516243A5 (cg-RX-API-DMAC7.html)
JP2015527318A5 (cg-RX-API-DMAC7.html)
JP2015534580A5 (cg-RX-API-DMAC7.html)
JP2014502266A5 (cg-RX-API-DMAC7.html)
MX2021014960A (es) Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2017537893A5 (cg-RX-API-DMAC7.html)
RU2015151046A (ru) Антитела против стеночной тейхоевой кислоты и их конъюгаты
JP2017527532A5 (cg-RX-API-DMAC7.html)
JP2018511628A5 (cg-RX-API-DMAC7.html)
JP2015528818A5 (cg-RX-API-DMAC7.html)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
JP2013512903A5 (cg-RX-API-DMAC7.html)
EA201890236A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение